Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Webcasts|October 10, 2019
GrantPlan: Create Grant Budgets with Confidence and Accuracy
Author(s)IQVIA Technologies
By using GrantPlan, the industry’s largest investigator grant database, teams can narrow down their budget inputs by choosing procedures that precisely match the protocol. They can also choose the exact rare disease indication. GrantPlan. Make precise decisions that are based on robust data and advanced analytics. Live: Thursday, Oct. 10, 2019 at 11am EDT On demand available after airing until Oct. 10, 2020. Register free: Register free
Register free:
Event Overview:
The complexities of modern trials offer little room for error. Intricate protocols are often coupled with large enrollment requirements, global site networks, shortened timelines and the always added pressure to deliver better results at lower costs.
GrantPlan helps mitigate the pressure:
- Drive Compliance
- Ensure FMV
- Eliminate Time-Consuming Searches
- Eradicate Uncertainty
…allowing your team to accurately budget and negotiate trials with confidence.
Key Learning Objectives:
IQVIA Technologies’ GrantPlan is the industry’s most comprehensive and accurate benchmarking tool, enabling organizations to confidently forecast, budget, and negotiate investigator grant costs electronically.
GrantPlan is accurate because it employs more data than any other industry tool available providing accurate FMV costs.
Speakers: Mike Jozefowicz, Associate Director, IQVIA Technologies
Alex McSherry, Associate Director, IQVIA Technologies
Time and date: Thursday, Oct. 10, 2019 at 11am EDT
On demand available after airing until Oct. 10, 2020.
Sponsor: IQVIA Technologies
Register free:
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
Where AI Governance in Clinical Development Falls Short
5